Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery
Recruiting · NCT07098780 · Interventional (participants receive a specific treatment) · Lead sponsor: Patel Hospital, Pakistan
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are: Does TXA reduce the amount of blood loss during bariatric surgery? Are there any side effects or complications in patients who receive TXA? Researchers will compare TXA to standard care (no TXA) to see if it is effective in reducing bleeding. Participants will: Receive either TXA or no TXA (placebo) before surgery Undergo standard bariatric surgery (LSG or MGB) Have their blood loss, hemoglobin levels, and any complications monitored during and after surgery
Who can take part
Inclusion criteria
- Patients above 18 years of age AND
- Undergoing Laparoscopic Sleeve Gastrectomy and MGB
- Morbid obesity
Exclusion criteria
- Patients on anti-platelets/anti-coagulants
- Patients with inherited or acquired bleeding disorders
- Patients with any acute medical condition predisposing to bleeding
- Hormonal contraceptives
- Known Allery to TXA
- Female hormonal replacement therapy
Where it is running
1 location listed.
- Patel Hospital - Karachi, Sindh, Pakistan